Skip to main content
Advertisement

Main menu

  • Home
  • Content
    • Current Issue
    • Accepted Manuscripts
    • Article Preview
    • Past Issue Archive
    • Video Articles
    • AJNR Case Collection
    • Case of the Week Archive
    • Case of the Month Archive
    • Classic Case Archive
  • Special Collections
    • AJNR Awards
    • Low-Field MRI
    • Alzheimer Disease
    • ASNR Foundation Special Collection
    • Photon-Counting CT
    • View All
  • Multimedia
    • AJNR Podcasts
    • AJNR SCANtastic
    • Trainee Corner
    • MRI Safety Corner
    • Imaging Protocols
  • For Authors
    • Submit a Manuscript
    • Submit a Video Article
    • Submit an eLetter to the Editor/Response
    • Manuscript Submission Guidelines
    • Statistical Tips
    • Fast Publishing of Accepted Manuscripts
    • Graphical Abstract Preparation
    • Imaging Protocol Submission
    • Author Policies
  • About Us
    • About AJNR
    • Editorial Board
    • Editorial Board Alumni
  • More
    • Become a Reviewer/Academy of Reviewers
    • Subscribers
    • Permissions
    • Alerts
    • Feedback
    • Advertisers
    • ASNR Home

User menu

  • Alerts
  • Log in

Search

  • Advanced search
American Journal of Neuroradiology
American Journal of Neuroradiology

American Journal of Neuroradiology

ASHNR American Society of Functional Neuroradiology ASHNR American Society of Pediatric Neuroradiology ASSR
  • Alerts
  • Log in

Advanced Search

  • Home
  • Content
    • Current Issue
    • Accepted Manuscripts
    • Article Preview
    • Past Issue Archive
    • Video Articles
    • AJNR Case Collection
    • Case of the Week Archive
    • Case of the Month Archive
    • Classic Case Archive
  • Special Collections
    • AJNR Awards
    • Low-Field MRI
    • Alzheimer Disease
    • ASNR Foundation Special Collection
    • Photon-Counting CT
    • View All
  • Multimedia
    • AJNR Podcasts
    • AJNR SCANtastic
    • Trainee Corner
    • MRI Safety Corner
    • Imaging Protocols
  • For Authors
    • Submit a Manuscript
    • Submit a Video Article
    • Submit an eLetter to the Editor/Response
    • Manuscript Submission Guidelines
    • Statistical Tips
    • Fast Publishing of Accepted Manuscripts
    • Graphical Abstract Preparation
    • Imaging Protocol Submission
    • Author Policies
  • About Us
    • About AJNR
    • Editorial Board
    • Editorial Board Alumni
  • More
    • Become a Reviewer/Academy of Reviewers
    • Subscribers
    • Permissions
    • Alerts
    • Feedback
    • Advertisers
    • ASNR Home
  • Follow AJNR on Twitter
  • Visit AJNR on Facebook
  • Follow AJNR on Instagram
  • Join AJNR on LinkedIn
  • RSS Feeds

AJNR Awards, New Junior Editors, and more. Read the latest AJNR updates

EditorialEditorials

Stem Cells, Radial Glial Cells, and a Unified Origin of Brain Tumors

M. Castillo
American Journal of Neuroradiology March 2010, 31 (3) 389-390; DOI: https://doi.org/10.3174/ajnr.A1674
M. Castillo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • Responses
  • References
  • PDF
Loading

It is now clear that what we think of as groups of tumors (eg, astrocytomas, ependymomas, and medulloblastomas), based on their conventional histology, immunohistochemistry, and imaging features, comprise several subtypes of neoplasias that have specific biologic, molecular, and genetic features.1 Until recently, it was thought that ependymomas originated from neuroepithelial cells, glioblastomas from abnormal astrocytes, and medulloblastomas from primitive cells in the external granular layer, but there is now evidence that all originate from a special type of stem cell called the “radial glial cell” (RGC). Currently, the consensus of opinion is that most brain tumors also originate from the so-called “brain tumor stem cells” (of which RGCs are a subtype).1

Stem cells may be found in the embryo, placenta, fetal blood and fetus, and in adults. Adult stem cell lines are predominantly located in muscle, skin, bone marrow, liver, blood, eyes, and brain. Normally, brain stem cells differentiate into different types, giving origin to neurons, astrocytes, oligodendrocytes, and ependymal cells (the traditional “no new neuron” theory is incorrect and no longer accepted; neurogenesis is thought to be a constant activity throughout life).2 Neural stem cells have specific functional, molecular, and antigenic properties. Because stem cells are perennial, their functional integrity is at risk for malignant degeneration, but because brain stem cells are needed throughout our lifespan, they also tend to be inherently resistant to drugs and toxins.3 Brain stem cells have a large rate of proliferation, particularly those located in the subventricular zones (SVZ), and we know rapid proliferation may lead to genetic errors.4

When brain tumor stem cells mutate (4–7 mutations are needed before degeneration occurs), they can generate phenotypically diverse tumors. Within a specific tumor, brain tumor stem cells constitute only a small fraction of the total malignant cells.2 Mutations may be induced by intrinsic cell factors (“fragile” DNA) or extrinsic ones (viruses, carcinogens). A function of brain tumor stem cells is to maintain the bulk of differentiated tumor cells, as they harbor properties of self-renewal (they maintain their number through life), extensive proliferation, and an ability to change into different lines (at this phase they are called “tumor progenitor cells”), following a hierarchic rather than a stochastic model of growth.2 For example, mutated brain tumor stem cells stimulated by epidermal and fibroblast growth factors express neural markers such as nestin and CD133 (a cell surface protein), committing them to a neural lineage (conversely leukemia tumor stem cells express CD34 and are CD133-negative).

However, some stem neural tumor cells may be also CD133-negative.1 A practical difference is that CD133-positive cells tend to repair their DNA damage earlier and better and thus tend to be more resistant to radiation and chemotherapy; as such, glioblastomas respond very differently to treatment, depending on their CD133 status.1 Tumor stem cells responsible for medulloblastoma express BMI1 and sonic hedgehog effectors (GLI1–3), which positively regulate cell renewal and proliferation, thus making them more resistant to conventional treatments.1–4 Another important tumor suppressor is PTEN, which controls proliferation of brain stem cells. Glioblastomas with inactivation of PTEN have a more favorable prognosis.

As stated before, stem cells become tumor progenitor cells and, in turn, become differentiated tumor cells (1 or more distinct tumor cell pools may form).5 Stem cells may bypass this sequence to produce tumors with single and multiple cell lineages (ie, tumors arise directly from stem cells). If differentiated, tumor cells tend to give origin to brain tumors with a single lineage, but they may undergo dedifferentiation and produce tumors with multiple cell lineages.1,2 Most aggressive brain tumors harbor morphologically different cell types, suggesting that differentiation into multiple cellular lines occurs preferentially in them, whereas most benign tumors contain cells that are similar in shape and size.

It is interesting to note that in the human brain, most stem cells are located in the SVZ. Both supra- and infratentorially and when stimulated with carcinogens, cells in the SVZ become tumorigenic faster than those located elsewhere. In the SVZ, stem cells exist in the form of RGCs. RGCs remain quiescent until they receive transformational signals. It is not clear if RGCs, after receiving transformation signals, return to their initial stem cell configuration and then become tumorigenic or if they transform to tumor progenitor cells directly.1–4 In the cerebellum, depending upon the signals received, RGCs and stem cells may give origin to either ependymoma or medulloblastoma. Abnormal stem cells are also responsible for glioblastomas. Tumors with the highest incidence in humans—medulloblastomas and glioblastomas—both originate from abnormal brain stem cells. Not surprising, both of these tumors are CD133-positive (as they contain neuronal differentiation), which makes them prone to be diffuse and resistant to treatment. Their RGCs are thought to be genetically abnormal and harbor oncogenes that lead to production of transformative factors. Because abnormal RGCs generate tumor cells that migrate, glioblastomas tend to multifocality (the eventual geographic fate of normal RGCs is not known). In the rest of this editorial, I will concentrate on the role of the RGC in the genesis of ependymoma and its implications.

We know that there are 3 types of ependymoma based on location: cerebellar, supratentorial, and spinal (all occurring along the walls of ependymal-lined cavities). Except for the myxopapillary type, all 3 types have similar initial histology but different prognoses and sex predilections, occur at different ages (posterior fossa ones are found in the youngest patients), and have distinct clinical behaviors suggesting they are separate diseases (cerebral and cerebellar ones may become anaplastic, whereas spinal ones almost never do). Nowadays, these 3 tumor types are recognized as being different. Ependymomas arising in the cerebral hemispheres (nearly always outside but adjacent to the lateral ventricles in the region of the RGCs) express EPHB-EPHRIN and NOTCH signaling systems and show an abnormality in 9p21.3.1 Spinal cord ones express HOX (homeobox) genes and have an abnormal 22q12 (they arise around the central spinal canal in the ventral cord, as HOX genes are involved in the ventral/dorsal modeling of the cord), whereas those in the posterior fossa express AQP1, tend to have a balanced karyotype, and always arise in the SVZ, projecting in or outside of the fourth ventricle.1 Experiments have determined that the tumor progenitor cells in ependymoma correspond to RGCs.1 Transplantation of these RGC-like cancer stem cells into the brains of rats produces ependymomas. It is also interesting to note that RGCs exposed to EMX2 give origin to supratentorial ependymoma in childhood but not in adults (EMX2 is a called a “negative regulator”). As neuroradiologists, we not uncommonly see protuberances of tissue of normal signal intensities along the walls of the lateral ventricles. These generally correspond to hyperplastic astrocytic polyps. Meddling with the function of EPHB-EPHRIN in the SVZ interrupts neuroblast migration resulting in astrocytic proliferation and formation of polyps.

What are the clinical implications of these discoveries? Normally, the human body defends its stem cells very well, so if brain tumors originate from these cells, it is safe to assume that the new lineages will be resistant to the damage induced by conventional radiation and chemotherapies. Emphasis is being placed on targeting the pathways that regulate the life cycles of cancer stem cells. For example, cells from ependymomas and certain leukemias produce a substance called γ-secretase, which is involved in aberrant cancer cell renewal via activation of NOTCH signaling. Inhibitors of this secretase are being tried in patients with leukemia and are being considered for treatment of children with advanced ependymoma within the US Pediatric Brain Tumor Consortium.1–5 Conventional therapies tend to kill normal and tumor cells but not the resistant brain tumor stem cells that eventually regenerate the tumor (this is the reason why glioblastomas always recur). In addition, the effect of conventional therapies on tumor cells is limited as they cannot effectively target all of the different cell lineages.

It is clear what we have historically called ependymomas comprise at least 3 tumors that are developmentally and molecularly distinct, and new and different treatments will be needed for each subgroup. Similarly, glioblastomas and medulloblastomas comprise different subtypes that determine patients' outcomes (at least 2 different glioblastoma subtypes are clearly recognizable). In the future, cultivation of individual brain tumor cells may lead to identification of specific molecular markers, which, in turn, may be used to prescribe personalized treatment protocols. Stem cells can also be engineered to produce substances (interleukins, metalloproteinases) that may induce tumor regression. Immortalized stem cells given through intravascular delivery migrate toward tumors. The use of stem cells as Trojan horses is currently experimental and it is possible that as they pass through the lung capillaries their migration towards the brain may be interrupted.

This topic is of enormous complexity, and I have attempted to simplify it. I have based—and extensively quoted—most of the information expressed here on the 5 references cited below. Anyone who is interested in this topic is encouraged to read these articles.

References

  1. 1.↵
    1. Taylor MD,
    2. Poppleton H,
    3. Fuller C,
    4. et al
    . Radial glial cells are candidate stem cells of ependymoma. Cancer Cell 2005;8:323–35
    CrossRefPubMed
  2. 2.↵
    1. Vescovi AL,
    2. Galli R,
    3. Reynolds BA
    . Brain tumour stem cells. Nat Rev Cancer 2006;6:425–36
    CrossRefPubMed
  3. 3.↵
    1. Pilkington GJ
    . Cancer stem cells in the mammalian central nervous system. Cell Prolif 2005;38:423–33
    CrossRefPubMed
  4. 4.↵
    1. Dirks PB
    . Brain tumor stem cells: bringing order to the chaos of brain cancer. J Clin Oncol 2008;26:2916–24
    Abstract/FREE Full Text
  5. 5.↵
    1. Piccirillo SG,
    2. Combi R,
    3. Cajola L,
    4. et al
    . Distinct pools of cancer stem-like cells coexist within human glioblastomas and display different tumorigenicity and independent genomic evolution. Oncogene 2009;28:1807–11. Epub 2009 Mar 16
    CrossRefPubMed
  • Copyright © American Society of Neuroradiology
PreviousNext
Back to top

In this issue

American Journal of Neuroradiology: 31 (3)
American Journal of Neuroradiology
Vol. 31, Issue 3
1 Mar 2010
  • Table of Contents
  • Index by author
Advertisement
Print
Download PDF
Email Article

Thank you for your interest in spreading the word on American Journal of Neuroradiology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Stem Cells, Radial Glial Cells, and a Unified Origin of Brain Tumors
(Your Name) has sent you a message from American Journal of Neuroradiology
(Your Name) thought you would like to see the American Journal of Neuroradiology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Cite this article
M. Castillo
Stem Cells, Radial Glial Cells, and a Unified Origin of Brain Tumors
American Journal of Neuroradiology Mar 2010, 31 (3) 389-390; DOI: 10.3174/ajnr.A1674

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
0 Responses
Respond to this article
Share
Bookmark this article
Stem Cells, Radial Glial Cells, and a Unified Origin of Brain Tumors
M. Castillo
American Journal of Neuroradiology Mar 2010, 31 (3) 389-390; DOI: 10.3174/ajnr.A1674
del.icio.us logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Purchase

Jump to section

  • Article
    • References
  • Info & Metrics
  • Responses
  • References
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Crossref (8)
  • Google Scholar

This article has been cited by the following articles in journals that are participating in Crossref Cited-by Linking.

  • Leptomeningeal Metastases in High-Grade Adult Glioma: Development, Diagnosis, Management, and Outcomes in a Series of 34 Patients
    Christopher Dardis, Kelly Milton, Lynn Ashby, William Shapiro
    Frontiers in Neurology 2014 5
  • The Subventricular Zone in Glioblastoma: Genesis, Maintenance, and Modeling
    Jamison Beiriger, Ahmed Habib, Nicolina Jovanovich, Chowdari V. Kodavali, Lincoln Edwards, Nduka Amankulor, Pascal O. Zinn
    Frontiers in Oncology 2022 12
  • Asymmetric cell division: Implications for glioma development and treatment
    Kate Lewis, Claudia Petritsch
    Translational Neuroscience 2013 4 4
  • Characterization of brain tumor initiating cells isolated from an animal model of CNS primitive neuroectodermal tumors
    Sergey Malchenko, Simone T. Sredni, Jerusha Boyineni, Yingtao Bi, Naira V. Margaryan, Maheedhara R. Guda, Yulia Kostenko, Tadanori Tomita, Ramana V. Davuluri, Kiran Velpula, Mary J.C. Hendrix, Marcelo B. Soares
    Oncotarget 2018 9 17
  • Neuro-oncological Disorders of the Cerebellum
    Thomas J. Pfiffner, Ronak Jani, Laszlo Mechtler
    Neurologic Clinics 2014 32 4
  • A Mouse Model of Human Primitive Neuroectodermal Tumors Resulting from Microenvironmentally-Driven Malignant Transformation of Orthotopically Transplanted Radial Glial Cells
    Sergey Malchenko, Simone Treiger Sredni, Hitoshi Hashimoto, Atsushi Kasai, Kazuki Nagayasu, Jianping Xie, Naira V. Margaryan, Kaoru Seiriki, Rishi R. Lulla, Richard E. B. Seftor, Lauren M. Pachman, Herbert Y. Meltzer, Mary J. C. Hendrix, Marcelo B. Soares, Keiko Abe
    PLOS ONE 2015 10 3
  • Fetal, Neonatal and Pediatric Neuroradiology
    Stephen Kralik, Nilesh Desai, Avner Meoded, Thierry Huisman
    2024
  • Outcomes of surgical treatment of periventricular IDH-wildtype glioblastoma
    K. A. Chizhova, D. A. Gulyaev, L. B. Mitrofanova, V. Yu. Chirkin, I. A. Kurnosov
    Vestnik nevrologii, psihiatrii i nejrohirurgii (Bulletin of Neurology, Psychiatry and Neurosurgery) 2024 10

More in this TOC Section

  • Teaching Lessons by MR CLEAN
  • Coffee Houses and Reading Rooms
  • Comeback Victory
Show more EDITORIALS

Similar Articles

Advertisement

Indexed Content

  • Current Issue
  • Accepted Manuscripts
  • Article Preview
  • Past Issues
  • Editorials
  • Editor's Choice
  • Fellows' Journal Club
  • Letters to the Editor
  • Video Articles

Cases

  • Case Collection
  • Archive - Case of the Week
  • Archive - Case of the Month
  • Archive - Classic Case

More from AJNR

  • Trainee Corner
  • Imaging Protocols
  • MRI Safety Corner

Multimedia

  • AJNR Podcasts
  • AJNR Scantastics

Resources

  • Turnaround Time
  • Submit a Manuscript
  • Submit a Video Article
  • Submit an eLetter to the Editor/Response
  • Manuscript Submission Guidelines
  • Statistical Tips
  • Fast Publishing of Accepted Manuscripts
  • Graphical Abstract Preparation
  • Imaging Protocol Submission
  • Evidence-Based Medicine Level Guide
  • Publishing Checklists
  • Author Policies
  • Become a Reviewer/Academy of Reviewers
  • News and Updates

About Us

  • About AJNR
  • Editorial Board
  • Editorial Board Alumni
  • Alerts
  • Permissions
  • Not an AJNR Subscriber? Join Now
  • Advertise with Us
  • Librarian Resources
  • Feedback
  • Terms and Conditions
  • AJNR Editorial Board Alumni

American Society of Neuroradiology

  • Not an ASNR Member? Join Now

© 2025 by the American Society of Neuroradiology All rights, including for text and data mining, AI training, and similar technologies, are reserved.
Print ISSN: 0195-6108 Online ISSN: 1936-959X

Powered by HighWire